Aptevo Therapeutics Inc. (APVO): Price and Financial Metrics

Aptevo Therapeutics Inc. (APVO)

Today's Latest Price: $35.74 USD

0.83 (-2.27%)

Updated Jan 27 9:31am

Add APVO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

APVO Stock Summary

  • With a year-over-year growth in debt of 683.79%, Aptevo Therapeutics Inc's debt growth rate surpasses 97.23% of about US stocks.
  • As for revenue growth, note that APVO's revenue has grown -63.12% over the past 12 months; that beats the revenue growth of merely 3.31% of US companies in our set.
  • In terms of volatility of its share price, APVO is more volatile than 98.2% of stocks we're observing.
  • Stocks that are quantitatively similar to APVO, based on their financial statements, market capitalization, and price volatility, are MNDO, ICCC, INS, AVEO, and MOSY.
  • Visit APVO's SEC page to see the company's official filings. To visit the company's web site, go to aptevotherapeutics.com.

APVO Stock Price Chart Interactive Chart >

Price chart for APVO

APVO Price/Volume Stats

Current price $35.74 52-week high $60.00
Prev. close $36.57 52-week low $2.94
Day low $35.74 Volume 1,234
Day high $36.33 Avg. volume 80,165
50-day MA $39.30 Dividend yield N/A
200-day MA $16.00 Market Cap 156.51M

Aptevo Therapeutics Inc. (APVO) Company Bio

Aptevo Therapeutics, a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company was spun off from Emergent BioSolutions Inc. in 2016 and is based in Seattle, Washington.

APVO Latest News Stream

Event/Time News Detail
Loading, please wait...

APVO Latest Social Stream

Loading social stream, please wait...

View Full APVO Social Stream

Latest APVO News From Around the Web

Below are the latest news stories about Aptevo Therapeutics Inc that investors may wish to consider to help them evaluate APVO as an investment opportunity.

Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial

SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial.

Yahoo Finance | January 11, 2021

Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Yahoo | January 6, 2021

Kaskela Law LLC Announces Investigation of Aptevo Therapeutics Inc. (APVO) and Encourages Shareholders to Contact the Firm

PHILADELPHIA, PA / ACCESSWIRE / December 19, 2020 / Kaskela Law LLC announces that it is investigating Aptevo Therapeutics Inc.

Yahoo | December 19, 2020

Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442

New Bispecific Therapeutic Candidate APVO442 uses ADAPTIR-FLEX Platform TechnologyAPVO442 is a Unique T-Cell Engager Designed to Target PSMA and CD3 for the Treatment of Prostate CancerSEATTLE, WA / ACCESSWIRE / December 2, 2020 / Aptevo Therapeutics Inc.

Yahoo | December 2, 2020

Global Bi Syndrome Treatment Market 2020:Quantitative Analysis By Aptevo THERAPEUTICS INC., OncoMed Pharmaceuticals, Inc., Roche, MacroGenics, Inc., AbbVie Inc., Regeneron Pharmaceuticals, Inc., Xencor

This Bi Syndrome Treatment report provides complete analysis of the market on global and regional level. It inspects the development rate and the market value dependent on the market elements and growth initiating factors. The market players

OpenPR | November 20, 2020

Read More 'APVO' Stories Here

APVO Price Returns

1-mo 4.44%
3-mo 442.34%
6-mo 325.48%
1-year 304.32%
3-year -24.25%
5-year N/A
YTD -2.48%
2020 299.98%
2019 -48.46%
2018 -70.05%
2017 73.77%
2016 N/A

Continue Researching APVO

Here are a few links from around the web to help you further your research on Aptevo Therapeutics Inc's stock as an investment opportunity:

Aptevo Therapeutics Inc (APVO) Stock Price | Nasdaq
Aptevo Therapeutics Inc (APVO) Stock Quote, History and News - Yahoo Finance
Aptevo Therapeutics Inc (APVO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8804 seconds.